Healthcare >> CEO Interviews >> August 6, 2001
ROBERT J. TOWARNICKI is President and Chief Executive Officer of
Nucleonics Inc. Mr. Towarnicki most recently served as Chairman,
President and CEO of Cell Pathways, Inc., an emerging pharmaceutical
company with two drugs in the clinic and one in-licensed commercial
product. Cell Pathways was acquired by OSI Pharmaceuticals in June 2003
for more than $80 million in stock and a Contingent Value Right (CVR)
that will be paid out in additional OSI stock if an NDA is filed for one
of the two lead Cell Pathways drugs within five years of the
acquisition. During his six-year tenure, Mr. Towarnicki led the
expansion of the company from a virtual organization to a fully
integrated, NASDAQ listed, emerging pharmaceutical company. Prior to
joining Cell Pathways, Mr. Towarnicki led the development of Integra
LifeSciences Corporation as President and COO, again building a company
from a small virtual organization into a full-fledged medical device
company trading on the NASDAQ during his five years of employment.
Experience prior to Integra LifeSciences includes: General Manager of
Focus Technologies, a privately held esoteric disease reference
laboratory; VP of Development and Operations for Collagen Corporation;
Plant Manager for Pfizer Pharmaceuticals and 10 years of increasing
management responsibility in operations for Merck & Co. Mr. Towarnicki
earned a BS and MS in Biology from Villanova University in 1973 and 1974
respectively. Profile
Mr. Towarnicki: Cell Pathways is a development stage pharmaceutical
company focused on the research, development and
